122804-37-9

Upstream product

• 100-39-0 benzyl bromide 
• 130325-65-4 (2R,3S)-1-benzyloxy-2,3-epoxy-3,7-dimethyl-6-octene 
• 106-24-1 Geraniol 
• 144666-93-3 (2S,3R)-3-Benzyloxymethyl-2-methyl-2-(4-methyl-pent-3-enyl)-oxirane 
• 122804-35-7 (2R,3R)-1-benzyloxy-3-methoxy-3,7-dimethyl-6-octene-2-ol 
• 62777-72-4 (2R,3S)-2,3-epoxynerol 

Downstream Products

• 122804-38-0 (2R,3R)-1-benzyloxy-2-t-butyldimethylsiloxy-3-methoxy-3-methyl-6-heptene 

Relevant academic research and scientific papers

USE OF MEXIPROSTIL IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE AND/OR OF IRRITABLE BOWEL SYNDROME

The invention relates to the use of mexiprostil in the treatment and/or prevention of inflammatory bowel disease and of irritable bowel syndrome, to the combinations of mexiprostil with other drugs, and also to a novel method for the synthesis of mexipros

Towards a Large Scale Preparation of Mexiprostil

The enantioselective synthesis of mexiprostil (16R-16-methoxy-16-methyl PGE1 methyl ester) is described.The assembly of the prostaglandin framework has been accomplished by the three component coupling process, via consecutive linking of the ω

Improvement process for debrominative rearrangements

This invention relates to an improvement in the standard procedures involving a debrominative rearrangement reaction of a terminal dibromoolefin with activated magnesium in tetrahydrofuran.